3SBio Inc. has announced the signing of an exclusive licensing agreement with Pfizer Inc. for the development of a PD-1/VEGF bispecific antibody known as SSGJ-707. This agreement is a strategic move aimed at bringing the innovative treatment to patients worldwide. Additionally, 3SBio revealed that there is a possibility of Pfizer subscribing to a number of new shares of the company, although no binding agreement has been reached on this potential subscription. The company advises shareholders and potential investors to exercise caution when dealing with its shares. The agreement also includes an option for Pfizer to commercialize the licensed product in mainland China, pending regulatory approvals. Morgan Stanley Asia Limited and Han Kun Law Offices are advising 3SBio on this transaction.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.